The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Our Staff & Volunteers
    • The Antibody Society’s Standing Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Executive Committee
      • Finance & Audit Committee
      • Governance & Nominating Committee
      • Initiatives Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Biopharmaceutical Informatics Symposium
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2022
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2022
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Research Competitions
    • Science Writing Competition
      • Science Writing Competition Winners
    • Discount codes for meeting registration
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / About / Board of Directors / Andreas Plückthun, Ph.D.

Andreas Plückthun, Ph.D.

pluckthun-bwAndreas Plückthun, Ph.D., is a Professor of Biochemistry and Director of the Department of Biochemistry at the University of Zurich, Switzerland. His research is centered on protein engineering. His contributions have included many aspects of antibody engineering, protein expression technology, design of synthetic antibody libraries, the development of ribosome display as an in vitro protein evolution technology, development of new scaffolds (the DARPin technology), and recently the directed evolution of G-protein coupled receptors towards high stability, which has allowed determination of their crystal structures.
His work has been published in over 380 papers, which have been cited over 20,000 times (h-index 86). He is an inventor on more than 20 patent families. In 2003 he was elected as member of the German Academy of Science (Leopoldina).
He received the Young Investigator’s Award of the German Industry Fund and was elected member of EMBO. In 2000, he received the Karl-Heinz-Beckurts Award (Germany) and in 2001 he became a finalist in the World Technology Awards in the Biotechnology category. In 2002 he received the J. P. Morgan Chase Award of The Tech Museum of Innovation (San Jose, USA), the Wilhelm-Exner-Medal (Vienna, Austria) and The Jury’s Grand Prix of the European Grand Prix for Innovation Awards (Monaco).  In 2005 he received, together with a team from Molecular Partners, the deVigier Award and the Swiss Technology Award. In 2011 he was awarded a Senior Investigator Grant of the European Research Council.
In 1992, he co-founded the Munich biotech company MorphoSys AG (TecDAX: MOR).  In 2004 he co-founded the biotech company Molecular Partners AG in Zurich (SIX: MOLN).
He studied chemistry at the University of Heidelberg (Germany) and received his graduate education at the University of California at San Diego, where he obtained a Ph.D. in 1982 with Prof. Edward Dennis. He was a postdoctoral fellow at the Chemistry Department of Harvard University (1982-85) where he worked with Prof. Jeremy Knowles. From 1985 until 1993, he was group leader at the Genzentrum and Max-Planck-Institut für Biochemie in Martinsried (Germany). He was appointed to the faculty of the University of Zürich (Switzerland) as a Full Professor of Biochemistry in 1993.

  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals